134 related articles for article (PubMed ID: 9741220)
1. [Hodgkin's disease. An old disease with a new face].
Giraldo P; Franco E
Sangre (Barc); 1998 Jun; 43(3):171-3. PubMed ID: 9741220
[No Abstract] [Full Text] [Related]
2. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
[TBL] [Abstract][Full Text] [Related]
3. Hodgkin's disease.
Longo DL; Banks PM; Hoppe RT
Rev Invest Clin; 1994 Apr; Suppl():73-83. PubMed ID: 7886314
[No Abstract] [Full Text] [Related]
4. Results of management in Hodgkin's disease.
Krishna A; Arya LS; Upadhyaya P
Indian Pediatr; 1988 Aug; 25(8):744-9. PubMed ID: 3220561
[No Abstract] [Full Text] [Related]
5. New therapies in Hodgkin's lymphoma.
Bartlett N
Clin Adv Hematol Oncol; 2004 Feb; 2(2):80, 83. PubMed ID: 16163165
[No Abstract] [Full Text] [Related]
6. [Clinical evaluation of patients with Hodgkin's disease treated at the Institute of Hematology 1974-1983].
Kopeć I; Leszko B; Słomkowski M; Pawelski S; Maj S
Acta Haematol Pol; 1988; 19(3-4):126-36. PubMed ID: 3252661
[No Abstract] [Full Text] [Related]
7. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.
Bonadonna G; Bonfante V; Viviani S; Di Russo A; Villani F; Valagussa P
J Clin Oncol; 2004 Jul; 22(14):2835-41. PubMed ID: 15199092
[TBL] [Abstract][Full Text] [Related]
8. [Lymphoma].
Mohar A; Sobrevilla-Calvo P; Velasquez WS
Rev Invest Clin; 1997 May; 49 Suppl 1():56-63. PubMed ID: 9380990
[No Abstract] [Full Text] [Related]
9. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
12. Hodgkin's disease.
Weinshel EL; Peterson BA
CA Cancer J Clin; 1993; 43(6):327-46. PubMed ID: 8242436
[TBL] [Abstract][Full Text] [Related]
13. Hodgkin's lymphoma involving the CNS.
Morawa E; Ragam A; Sirota R; Nabhan C
J Clin Oncol; 2007 Apr; 25(11):1437-8. PubMed ID: 17416864
[No Abstract] [Full Text] [Related]
14. Hodgkin's disease - new treatment strategies toward the cure of patients.
Jox A; Sieber M; Wolf J; Diehl V
Cancer Treat Rev; 1999 Jun; 25(3):169-76. PubMed ID: 10425259
[No Abstract] [Full Text] [Related]
15. What is the optimal treatment volume in Hodgkin's disease patients undergoing high-dose chemotherapy and adjuvant radiation therapy?
Mundt AJ; Connell PP; Mansur DB
Radiat Oncol Investig; 1999; 7(6):353-9. PubMed ID: 10644058
[TBL] [Abstract][Full Text] [Related]
16. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
Sieniawski M; Franklin J; Nogova L; Glossmann JP; Schober T; Nisters-Backes H; Diehl V; Josting A
J Clin Oncol; 2007 May; 25(15):2000-5. PubMed ID: 17420510
[TBL] [Abstract][Full Text] [Related]
17. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
Akhtar S; El Weshi A; Abdelsalam M; Hussaini H; Janabi I; Rahal M; Maghfoor I
Bone Marrow Transplant; 2007 Oct; 40(7):651-8. PubMed ID: 17660837
[TBL] [Abstract][Full Text] [Related]
18. Treatment of relapses in aggressive non Hodgkin's lymphoma.
Bosly A
Bull Cancer; 2004; 91(7-8):E261-73. PubMed ID: 15381464
[TBL] [Abstract][Full Text] [Related]
19. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens.
Ardeshna KM; Kakouros N; Qian W; Powell MG; Saini N; D'Sa S; Mackinnon S; Hoskin PJ; Goldstone AH; Linch DC
Br J Haematol; 2005 Aug; 130(3):363-72. PubMed ID: 16042685
[TBL] [Abstract][Full Text] [Related]
20. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
Cooney JP; Stiff PJ; Toor AA; Parthasarathy M
Biol Blood Marrow Transplant; 2003 Mar; 9(3):177-82. PubMed ID: 12652468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
